Precigen Inc
PGEN3.800USD
-0.020-0.52%
Fechamento 09/18, 16:00（ET）Cotações atrasadas em 15 min
1.13BValor de mercado
PerdaP/L TTM
Mais detalhes de Precigen Inc Empresa
Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Company’s proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Informações da empresa
Código da empresaPGEN
Nome da EmpresaPrecigen Inc
Data de listagemAug 08, 2013
CEODr. Helen Sabzevari, Ph.D.
Número de funcionários143
Tipo de títulosOrdinary Share
Fim do ano fiscalAug 08
Endereço20374 Seneca Meadows Parkway
CidadeGERMANTOWN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal20876
Telefone13015569900
Sitehttps://precigen.com/
Código da empresaPGEN
Data de listagemAug 08, 2013
CEODr. Helen Sabzevari, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.32M
+20.22%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.15M
+12.00%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.14M
+11.34%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
595.77K
+26.11%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
579.24K
+27.13%
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
520.43K
+32.30%
Ms. Nancy Howell Agee
Ms. Nancy Howell Agee
Independent Director
Independent Director
217.84K
+7.39%
Mr. Phil Tennant
Mr. Phil Tennant
Chief Commercial Officer
Chief Commercial Officer
59.03K
+279.40%
Mr. Cesar L. Alvarez
Mr. Cesar L. Alvarez
Independent Director
Independent Director
--
--
Mr. Donald P. Lehr
Mr. Donald P. Lehr
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.32M
+20.22%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.15M
+12.00%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.14M
+11.34%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
595.77K
+26.11%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
579.24K
+27.13%
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
520.43K
+32.30%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Service
1.11M
83.15%
Product
203.00K
15.14%
Other
23.00K
1.72%
Sem dados
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Service
1.11M
83.15%
Product
203.00K
15.14%
Other
23.00K
1.72%
Distribuição de ações
Atualizado em: sáb, 16 de ago
Atualizado em: sáb, 16 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Third Security, LLC
39.04%
Merck Serono SA
6.93%
Patient Capital Management, LLC
5.46%
Adage Capital Management, L.P.
3.78%
BlackRock Institutional Trust Company, N.A.
3.30%
Outro
41.48%
Investidores
Investidores
Proporção
Third Security, LLC
39.04%
Merck Serono SA
6.93%
Patient Capital Management, LLC
5.46%
Adage Capital Management, L.P.
3.78%
BlackRock Institutional Trust Company, N.A.
3.30%
Outro
41.48%
Tipos de investidores
Investidores
Proporção
Venture Capital
39.09%
Investment Advisor
15.25%
Corporation
6.93%
Investment Advisor/Hedge Fund
5.74%
Hedge Fund
5.46%
Individual Investor
3.54%
Research Firm
1.17%
Bank and Trust
0.07%
Insurance Company
0.04%
Outro
22.71%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
298
229.52M
77.76%
-784.34K
2025Q1
334
228.75M
77.50%
-12.95M
2024Q4
336
223.34M
76.44%
-15.36M
2024Q3
342
222.44M
77.88%
+21.14M
2024Q2
350
183.56M
71.33%
-22.34M
2024Q1
356
187.95M
73.95%
-17.15M
2023Q4
369
187.18M
73.43%
-12.81M
2023Q3
377
185.65M
75.06%
-11.67M
2023Q2
383
181.15M
73.32%
-8.55M
2023Q1
397
185.25M
75.25%
+14.81M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Third Security, LLC
116.34M
39.41%
-507.18K
-0.43%
Mar 31, 2025
Merck Serono SA
20.65M
6.99%
--
--
Mar 31, 2025
Patient Capital Management, LLC
17.37M
5.89%
-508.94K
-2.85%
Mar 31, 2025
Adage Capital Management, L.P.
11.28M
3.82%
+410.60K
+3.78%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
9.56M
3.24%
+209.48K
+2.24%
Mar 31, 2025
The Vanguard Group, Inc.
8.80M
2.98%
+465.47K
+5.59%
Mar 31, 2025
Iridian Asset Management LLC
4.59M
1.55%
-656.11K
-12.52%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.48M
1.18%
+179.75K
+5.45%
Mar 31, 2025
Sabzevari (Helen)
3.32M
1.12%
+557.91K
+20.22%
May 16, 2025
State Street Global Advisors (US)
3.04M
1.03%
+64.16K
+2.16%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de set
Atualizado em: sáb, 6 de set
Nome
Proporção
Inspire Small/Mid Cap ESG ETF
0.64%
Innovator US Small Cap Managed Floor ETF
0.14%
Invesco Nasdaq Biotechnology ETF
0.14%
Vanguard US Momentum Factor ETF
0.11%
iShares Biotechnology ETF
0.07%
iShares Micro-Cap ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.05%
iShares Russell 2000 Growth ETF
0.04%
Invesco Russell 2000 Dynamic Multifactor ETF
0.03%
Fidelity Enhanced Small Cap ETF
0.02%
Ver Mais
Inspire Small/Mid Cap ESG ETF
Proporção0.64%
Innovator US Small Cap Managed Floor ETF
Proporção0.14%
Invesco Nasdaq Biotechnology ETF
Proporção0.14%
Vanguard US Momentum Factor ETF
Proporção0.11%
iShares Biotechnology ETF
Proporção0.07%
iShares Micro-Cap ETF
Proporção0.06%
ProShares Ultra Nasdaq Biotechnology
Proporção0.05%
iShares Russell 2000 Growth ETF
Proporção0.04%
Invesco Russell 2000 Dynamic Multifactor ETF
Proporção0.03%
Fidelity Enhanced Small Cap ETF
Proporção0.02%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
